Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

PPBT

Purple Biotech (PPBT)

Purple Biotech Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PPBT
DateTimeSourceHeadlineSymbolCompany
05/06/202406:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
03/06/202420:21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
01/06/202422:00GlobeNewswire Inc.Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerNASDAQ:PPBTPurple Biotech Ltd
21/05/202421:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
21/05/202421:30GlobeNewswire Inc.Purple Biotech Reports First Quarter 2024 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
25/04/202421:00GlobeNewswire Inc.Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual MeetingNASDAQ:PPBTPurple Biotech Ltd
28/03/202422:00GlobeNewswire Inc.Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024NASDAQ:PPBTPurple Biotech Ltd
14/03/202422:30GlobeNewswire Inc.Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyNASDAQ:PPBTPurple Biotech Ltd
07/03/202408:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
06/03/202408:00Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:PPBTPurple Biotech Ltd
05/03/202423:58Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
05/03/202423:55GlobeNewswire Inc.Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
27/02/202423:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
27/02/202423:00GlobeNewswire Inc.Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024NASDAQ:PPBTPurple Biotech Ltd
13/02/202423:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
13/02/202423:00GlobeNewswire Inc.Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 TrialNASDAQ:PPBTPurple Biotech Ltd
01/02/202423:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
01/02/202423:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
01/02/202423:30GlobeNewswire Inc.Purple Biotech Reaches Recommended Phase 2 Dose for NT219NASDAQ:PPBTPurple Biotech Ltd
27/01/202408:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
21/12/202300:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
21/12/202300:05GlobeNewswire Inc.Purple Biotech Appoints Dr. Yael Margolin to its Board of DirectorsNASDAQ:PPBTPurple Biotech Ltd
14/12/202323:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
14/12/202322:50GlobeNewswire Inc.Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer TrialNASDAQ:PPBTPurple Biotech Ltd
21/11/202323:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
21/11/202322:50GlobeNewswire Inc.Purple Biotech Reports Third Quarter 2023 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
15/11/202316:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PPBTPurple Biotech Ltd
15/11/202308:13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PPBTPurple Biotech Ltd
14/11/202308:11Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:PPBTPurple Biotech Ltd
02/11/202322:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
 Showing the most relevant articles for your search:NASDAQ:PPBT

Your Recent History

Delayed Upgrade Clock